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CObjectives: Bevacizumab is approved for treatment of advanced non-
small cell lung cancer (NSCLC) in combination with chemotherapy
based on a 2-month median survival benefit demonstrated in one ran-
domized trial. The cost-utility of adding bevacizumab to chemotherapy
in advanced NSCLC remains unknown.We evaluated the cost-utility of
bevacizumab added to chemotherapy in patients with advanced
NSCLC. Methods: We developed a Markov model to estimate quality-
djusted life years (QALYs) and direct medical costs from the US payer
erspective in patients treated with bevacizumab plus chemotherapy
nd compared these outcomes with patients treated with chemother-
py alone. We populated the model with survival and toxicity data from
he clinical trial that compared the two strategies. We obtained utilities
rom a literature search and unit costs from Medicare. We discounted
ALYs and costs at 3% per year.We addressed uncertainty with one-way
nd probabilistic sensitivity analyzes. Results: Compared with chemo- O
N, M
al So
oi:10.1016/j.jval.2011.04.004herapy alone, bevacizumab and chemotherapy increased mean QALYs
y 0.13, at an incremental life-time cost of US$72,000 per patient. The
ncremental cost-utility ratio (ICUR)wasUS$560,000/QALY. The ICURwas
ost sensitive to the survival on bevacizumab treatment, the drug costs
fbevacizumab,and theutilityof stablediseaseon treatment.Ata thresh-
ld of US$100,000/QALY, the addition of bevacizumab had a 0.2% proba-
ility of being cost-effective. Conclusions: Bevacizumab does not ap-
ear to be cost-effective when added to chemotherapy in patients with
dvanced NSCLC, based on approximate cost-effectiveness thresholds
hat have been identified in the United States. These results may in-
orm decision-makers about resource allocation for NSCLC care.
eywords: bevacizumab, cancer, chemotherapy, cost-effectiveness,
ost-utility, lung.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Advanced non-small cell lung cancer (NSCLC) is an incurable dis-
ease that carries a poor prognosis. Patients with advanced NSCLC
have a median overall survival (OS) of 4 to 5 months and a 1-year
OS of 20% to 25% if untreated [1,2]. For these patients, palliative
hemotherapy remains the standard of care. Several randomized
ontrol trials and meta-analyses have shown that chemotherapy
ncreases median overall survival by 2 months compared with
est supportive care (BSC), and improves cancer-related symp-
oms [1,2]. The standard first-line chemotherapy regimens include
latinum-doublet combinations for patients with good performance
tatus (Eastern Cooperative Oncology Group [ECOG] performance
core of 0-1). Bevacizumab, an anti-VEGF monoclonal antibody, re-
eived approval in October 2006 for first-line treatment in combina-
ionwith carboplatin andpaclitaxel based ona 2-monthmedian sur-
ival benefit demonstrated in the ECOG 4599 randomized trial [3,4].
Current clinical guidelines recommend adding bevacizumab to first-
line platinum-doublet regimens for patientswith advanced or recur-
rent non-squamous non-small cell lung cancer who meet clinical
criteria for bevacizumab treatment [5].
Although the addition of bevacizumab to chemotherapy re-
sulted in a modest survival benefit, its acquisition costs are high
* Address correspondence to: Bernardo Goulart, 1100 Fairview Ave
E-mail: bgoulart@fhcrc.org or bhg@uw.edu.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.and its use is common among oncologists [6,7]. Given the rapidly
rising costs of cancer drugs in the context of scarce resources,
decision-makers may use cost-effectiveness data to inform their
decisions about resource allocation for cancer care [8]. A cost-util-
ity analysis performed alongside one randomized trial suggested
that chemotherapy is cost-effective compared to BSC [9]. Three
studies have addressed the cost-effectiveness of the addition of
bevacizumab to chemotherapy in NSCLC [10–12]. Two of these
studies used indirect treatment comparison methods to deter-
mine the cost-effectiveness of cisplatin and pemetrexed relative
to other regimens including carboplatin, paclitaxel, and bevaci-
zumab [10] and to determine the cost-effectiveness of cisplatin,
gemcitabine, and bevacizumab versus cisplatin and pemetrexed
[11]. The third study reported a cost-effectiveness ratio of
US$345,762 per year of life gained for the addition of bevacizumab
to carboplatin and paclitaxel [12]. The results of the first two stud-
ies are limited by the lack of randomized clinical trial data com-
paring the different strategies, and included trials using different
doses of bevacizumab. The third study was presented as an ab-
stract, and did not include any sensitivity analysis [12]. Therefore,
the cost-effectiveness and cost-utility of bevacizumab and che-
motherapy compared with chemotherapy alone remains unclear.
We performed a cost-effectiveness and cost-utility analysis of the
addition of bevacizumab to chemotherapy compared to chemo-
/S: M3-B232, Seattle, WA 98109-1024.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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837V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5therapy alone in patients with advanced non-squamous NSCLC,
taking the US health care payer perspective.
Methods
We developed a Markov model in Microsoft Excel (Microsoft, Inc.,
Redmond, WA) to estimate life expectancy, quality-adjusted life
years (QALYs), and direct medical costs from the US health care
payer perspective of patients diagnosed with stage IIIB/IV NSCLC
who are candidates for first-line palliative chemotherapy with be-
vacizumab. Based on inclusion criteria from the clinical trial, pa-
tients in the model had non-squamous NSCLC tumor histologies,
no brain metastasis, an ECOG performance status of 0 or 1, ade-
quate renal and liver functions, adequate blood cell counts, no
history of hemoptysis of more than 1/2 table spoon per event, no
history of coagulopathy, and were not on therapeutic anticoagu-
lation or taking an aspirin dose 325 mg or other nonsteroidal
nti-inflammatory agents.
Model structure
We included the following Markov states in the model: stable dis-
ease on therapy (SDtx), stable disease off therapy (SDoff), fever and
neutropenia (FN), severe bleeding, progressive disease (PD), and
death. Figure 1 illustrates these Markov states and their possible
ransitions.We considered FNand severe bleeding as health states
ecause thesewere complications from treatment associatedwith
risk of death and detrimental effect on quality of life, as well as
otential drivers of medical costs. Themodel had a cycle length of
month (i.e., the model estimated patients’ probabilities of tran-
itioning between states for each month over a time horizon of 4
ears). This time horizon was appropriate to estimate life expec-
ancy in this patient population [13]. Patients entered themodel in
he stable disease on therapy state. Patients could move from this
tate to the FN state, severe bleeding state, or PD state. The model
Fig. 1 – Schematic representation of the Markov model.
Patients in the carboplatin and paclitaxel (CP) group moved
from stable disease on therapy state to stable disease off
therapy state after six cycles of CP (thick broken arrow
above). Patients in the carboplatin, paclitaxel, and
bevacizumab group remained in the stable disease on
therapy state until disease progression or a severe
bleeding episode, after which they could move to the
stable disease off therapy state or die. Tx, treatment.ssumed that patients could stay for only one cycle (1 month) in tthe FN or severe bleeding states, and that FN and severe bleeding
are mutually exclusive events. Patients who experienced a severe
bleeding episode could not go back to therapy, and moved to the
stable disease off therapy state or died. Patients who experienced
a FN episode could go back to the stable disease on therapy state or
die. In the carboplatin-paclitaxel (CP) group, all patients who did
not experience progressive disease or died moved to the stable
disease off therapy state after six cycles of chemotherapy. In the
carboplatin-paclitaxel-bevacizumab (CPB) group, all patients re-
mained in the stable disease on therapy state until progressive
disease or severe bleeding to reflect treatment with maintenance
bevacizumab after six cycles of chemotherapy plus bevacizumab.
In the case of severe bleeding, patients on carboplatin-paclitaxel-
bevacizumabmoved to the stable disease off therapy state or died.
Patients couldmove to the PD state fromboth stable diseases on or
off therapy states. The model assumed that patients could move
to the death state only from the progressive disease, FN, or severe
bleeding states.
Clinical data
We based the treatments, probability of toxicities, and outcomes
on data from the pivotal ECOG 4599 clinical trial, which was a
randomized phase III trial of patients with advanced predomi-
nantly nonsquamous NSCLC [3]. The study compared six cycles of
carboplatin (area under the curve [AUC]  6) and paclitaxel (200
mg/m2) given intravenously every 3 weeks with the same chemo-
herapy regimen plus bevacizumab (15 mg/kg) given intrave-
ously every 3weeks for six cycles [3,4,14]. Patients randomized to
he bevacizumab arm that did not experience disease progression
r prohibitive toxicity after six cycles remained on maintenance
evacizumab alone every 3 weeks until disease progression, pro-
ibitive toxicity, or consent withdrawn. The trial did not allow
atients in the CP group to cross over to the CPB group at any time
uring the study. The primary end-point of the trial was overall
urvival (OS), and secondary end-points included progression-free
urvival (PFS), response rates, and toxicity. Median follow-up was
9months. Table 1 describes the trial demographic data, aswell as
fficacy and toxicity results.
Outcomes
From the aforementioned study, the median OS was 10.3 months
for the chemotherapy-only group (CP) and 12.3 months for the
chemotherapy plus bevacizumab group (CPB), with a hazard ratio
for death of 0.79 and a 95% confidence interval (CI) of 0.67 to 0.92.
The median PFS was 4.5 months for the CP group and 6.2 months
for the CPB group (HR0.66; 95% CI 0.57–0.77). We applied
the formula below to calculate the transition probabilities from
stable disease on therapy to FN; stable disease on therapy to se-
vere bleeding; stable disease on therapy to PD; FN to death; severe
bleeding to death; stable disease off therapy to PD; and PD to
death: tp  1  (1P)1/t; where tp represents the transition proba-
ility, P represents the cumulative probability of death, tumor pro-
ression, FN, or severe bleeding at time t,measured inmonths.We
sed the median OS and PFS times (where P  0.5) to calculate
ransition probabilities of death and tumor progression in each
roup. We used the median follow-up time of 19 months to calcu-
ate the transition probabilities of stable disease on therapy to FN
nd severe bleeding, respectively. Because our model allowed pa-
ients to stay in the FN and severe bleeding states for only 1-month
ycle, the transition probabilities of FN and severe bleeding states
o death were the actual cumulative probabilities of death from
hese events as reported in the ECOG 4599 trial, respectively. We
alculated the cumulative probabilities of death from FN and se-
ere bleeding by dividing the number of deaths from these adverse
vents by the number of patients who suffered severe forms of
hese events in the trial (grades 3 to 5). We used the median time
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838 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5interval from disease progression to death to calculate the transi-
tion probability of death from progressive disease (Tables 2A and
2B). The model assumed a constant hazard rate over time. We
calculated life expectancy (OS) by adding up the mean time spent
in all states other than death, and mean PFS by subtracting the
mean time in the progressive disease state from total life expec-
tancy (OS).We assessed the validity of themodel by comparing life
expectancy estimated from themodel with observed trial survival
data in both groups. We estimated life expectancy directly from
the trial by calculating the survival AUC in both groups, respec-
tively. Figure 2 shows the model survival estimate plots for both
roups.
Health state utilities
We used health state utility information from the literature to
represent each health state that patients with advanced NSCLC
experienced in this model. Utility scores are measures from 0 to 1
Table 1 – Characteristics of patients and clinical
parameters from the ECOG 4599 trial [4,5].
Characteristic CP group
n  433
N (%)
CPB group
n  417
N (%)
Sex
Male 253 (58) 210 (50)
Female 180 (42) 207 (50)
Age  65 years 189 (44) 177 (42)
Race
White 378 (91) 352 (90)
Black 23 (6) 22 (6)
Other 14 (3) 17 (4)
ECOG performance status
0 170 (40) 167 (40)
1 260 (60) 247 (60)
Prior weight loss (5%)
121 (28) 117 (28)
Stage
IIIB 55 (13) 50 (12)
IV 337 (78) 310 (74)
Recurrent disease 40 (9) 57 (14)
Prior radiation therapy 37 (9) 33 (8)
Efficacy results
Survival
Median (months) 10.3 12.3
Hazard ratio (95% CI) 0.79 (0.67–0.92)
Progression-free survival
Median (months) 4.5 6.2
Hazard ratio (95% CI) 0.66 (0.57–0.77)
Toxicity (grades 3 to 4) N (%) N (%)
Fever and neutropenia 8 (1.8) 17 (4.0)
Neutropenia 74 (16.8) 109 (25.5)
Anemia 4 (0.9) 0 (0)
Thrombocytopenia 1 (0.2) 7 (1.6)
Hypertension 3 (0.7) 30 (7.0)
Proteinuria 0 (0) 13 (3.1)
Headache 2 (0.5) 13 (3.0)
Rash or desquamation 2 (0.5) 10 (2.3)
Severe Bleeding 3 (0.7) 22 (5.1)
Toxic deaths
Fever and neutropenia 1 (0.2) 5 (1.2)
Bleeding 1 (0.2) 7 (1.7)
CP, carboplatin and paclitaxel group; CPB, carboplatin, paclitaxel, and
bevacizumab group; ECOG, Eastern Cooperative Oncology Group.used to quantify societal preferences for health states relative to aperfect health state (utility  1) and death (utility  0). We ob-
ained the health state utilities for stable disease on therapy, sta-
le disease off therapy, fever and neutropenia, and progressive
isease from two surveys of theUK general population and clinical
xperts, respectively, that evaluated specific advanced NSCLC
tates [15,16]. The clinical expert survey provided the utilities for
ever and neutropenia and progressive disease states after sec-
nd-line chemotherapy, and we extrapolated these utility values
o our study in first-line chemotherapy [16]. We obtained the util-
ty for severe bleeding from a cost-effectiveness analysis of
ariceal ligation for the prevention of esophageal variceal bleeding
n patients with liver cirrhosis [17]. The utility score corresponded
o the first episode of esophageal variceal bleeding, which is a
erious condition requiring admission to the hospital. Table 2A
escribes the utility values.
Costs
We estimated drug costs per patient by multiplying the mean
number of chemotherapy cycles by unit acquisition drug costs.We
calculated themean number of cycles based on the survival in the
stable disease on therapy state, assuming a 3-week chemotherapy
cycle. The estimated mean number of treatment cycles in the CP
and CPB groups was 4.71 and 11.32, respectively. This difference
reflects treatment with maintenance bevacizumab in CPB group
after six cycles of chemotherapy plus bevacizumab and observa-
tion in CP group after chemotherapy. In the CPB group, we as-
sumed that the first 6 cycles would consist of carboplatin, pacli-
taxel and bevacizumab, and the following 5.32 cycles would
consist of maintenance bevacizumab. We used 2010 average sales
price (ASP) from Centers of Medicare and Medicaid Services (CMS)
to estimate drug unit costs [18]. ASP is a weighted average of the
payments for Medicare part B drugs (including chemotherapy and
biologicals) made to manufacturers by multiple insurance plans
that contract with Medicare. ASP is the drug cost unit measure
recommended by the International Society of Pharmacoeconom-
Fig. 2 – Overall survival plots estimated from the model
and superimposed with Kaplan-Meier survival curves from
the Eastern Cooperative Oncology Group (ECOG) 4599 trial.
The light grey curves represent the model estimates of
overall survival for the carboplatin, paclitaxel, and
bevacizumab versus carboplatin and paclitaxel alone
groups, respectively. The model curves are superimposed
with the actual overall survival estimates for both groups
in the ECOG 4599 trial (solid dark line: carboplatin,
paclitaxel, and bevacizumab; dashed dark line: carboplatin
and paclitaxel). Reprinted from Sandler A, Gray R, Perry
MC, et al. Paclitaxel-carboplatin alone or with bevacizumab
for non-small-cell lung cancer. The New England Journal of
Medicine, 2006;355:2542–2550. ©2006, with permission
from Massachusetts Medical Society.
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839V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5ics andOutcomes ResearchGuidelines for cost-effectiveness stud-
ies that take the US government payer perspective [19]. We as-
sumed a 63-year-old average patient with aweight of 70 kg, a body
surface area of 1.8 m2, and a creatinine clearance of 70 ml/min to
calculate the mean doses of carboplatin (AUC  6), paclitaxel (200
mg/m2), and bevacizumab (15 mg/kg). The age above represents
he median age of patients enrolled in the ECOG 4599 trial and the
osages represent the original treatment plan in the trial [3]. We
ssumed no drug wastage. Infusion times consisted of 3 hours for
aclitaxel and 1 hour for carboplatin and bevacizumab, respec-
ively, for a total of 4 hours in the CP group and 5 hours in the CPB
roup. Total drug administration cost per patient was the product
f the unit cost of drug administration for each chemotherapy
egimen by the mean number of cycles. For maintenance bevaci-
umab, we assumed a 1-hour infusion only.
We obtained the inpatient costs of a FN episode and a severe
leeding episode from the CMS Prospective Payment System (PPS)
Table 2A – Model parameters and the range used for one-w
Parameters Base case 2
Drug (ASP)
Carboplatin ( 20%) 46.12
Paclitaxel ( 20%) 91.24
Bevacizumab ( 20%) 6136.10
Number of carboplatin and paclitaxel cycles
CP group 4.71
CP  bev group 6.00
Number of bevacizumab cycles (CBP) 11.32
Drug administration
CP  bev ( 20%) 398.08
CP ( 20%) 317.46
Bev alone ( 20%) 163.55
Side effects
Anemia ( 20%) 843.44
Neutropenia ( 20%) 144.13
Thrombocytopenia ( 20%) 144.13
FN episode (DRG 398) ( 20%) 11508.15
Severe bleeding episode (DRG174) ( 20%) 10415.48
Outpatient visits on and off treatment ( 20%) 88.61
PD (month) ( 20%) 6442.12
Health state utilities
SDtx 0.58
SDoff 0.63
FN 0.56
Severe bleeding 0.30
PD 0.47
Discount rate 0.03
Time spent in each state (years)
Time in SDtx w bev  chemo ( 95% CI) 0.705
Time in SDoff w bev  chemo ( 95% CI) 0.014
Time in FN w bev  chemo ( 95% CI) 0.0022
Time in bleed w bev  chemo ( 95% CI) 0.0019
Time in PD w bev  chemo ( 95% CI) 0.521
Time in SDtx w chemo alone ( 95% CI) 0.294
Time in SDoff w chemo alone ( 95% CI) 0.181
Time in FN w chemo alone ( 95% CI) 0.0003
Time in bleed w chemo alone ( 95% CI) 0.0001
Time in PD w chemo alone ( 95% CI) 0.537
Unit costs refer to 2010 US dollar amounts. Time spent in health stat
ASP, average sales price; bev, bevacizumab; bleed, severe bleeding; ch
carboplatin and paclitaxel; DRG, diagnosis related group code; ECOG,
sive disease; SDoff, stable disease off therapy; SDtx, stable disease ony identifying the respective diagnosis related group codes (DRG h98 for FN and DRG 174 for severe bleeding) [18]. We also included
n these costs one inpatient physician visit per day through the
eometric mean of the length of stay (4.6 days for FN, 3.8 days for
evere bleeding). The total costs for FN and severe bleeding were
he product of the costs of one episode by the mean time spent in
he FN and severe bleeding states, respectively. We calculated the
osts of grades 3 and 4 anemia, nonfebrile neutropenia, and
hrombocytopenia by multiplying the frequencies of these ad-
erse events (AEs) reported in the ECOG 4599 trial by their unit
osts, which we obtained from a budget impact model study of
econd and third-line therapies for advanced NSCLC [20]. We as-
umed one additional outpatient visit of “moderate to high sever-
ty” plus one red blood cell transfusion for anemia, and one addi-
ional outpatient visit for grades 3 and 4 neutropenia and
hrombocytopenia, respectively. We assumed no granulocyte-col-
ny growth factors (G-CSF) use or platelet transfusions. Other
rade 3 and 4 AEs reported by the trial included hypertension,
ensitivity analysis.
Range Source
Low High
36.90 55.35 CMS [18]
72.99 109.48
4908.88 7363.31
4 6
4 6
4 15
318.46 477.70
253.97 380.95 CMS [18]
130.84 196.26
674.75 1012.13 Ramsey et al. [20]
115.30 172.96
115.30 172.96 CMS [18]
9206.52 13809.78
8332.38 12498.58
70.89 106.33 CMS [18]
5153.70 7730.54 Yabroff et al. [21]
0.46 0.71 Doyle et al. [15]
0.46 0.71 Doyle et al. [15]
0.30 0.58 Nafees et al. [16]
0.27 0.33 Imperiale et al. [17]
0.30 0.58 Nafees et al. [16]
0.00 0.06
0.606 0.825 Ramalingam et al. [4]
0.012 0.016
0.0019 0.0026
0.0016 0.0022
0.443 0.604
0.253 0.344
0.155 0.211
0.00033 0.00044
0.00011 0.00015
0.456 0.623
reported in years.
chemotherapy; CMS, Centers forMedicare andMedicaid Services; CP,
rn Cooperative Oncology Group; FN, febrile neutropenia; PD, progres-
apy.ay s
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840 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5were uncommon, with a maximum frequency of 7% for hyperten-
sion. We assumed that these side effects were managed as part of
the planned outpatient visits during treatment and had no signif-
icant impact on costs or outcomes. The trial did not report the
frequencies of nausea and vomiting, and we assumed no signifi-
cant differences of nausea and vomiting between the two arms.
Outpatientmedical services costs included one outpatient visit
every 3weeks during treatment and onemonthly visit for patients
with stable disease off treatment. We used the Physician Fee
Schedule from CMS to obtain the unit cost of a visit qualified as an
“outpatient visit for the evaluation and management of an estab-
lished patient presenting with problems of low tomoderate sever-
ity” assuming that patients had a low burden of symptoms during
treatment and during follow-up in the stable disease state [18].
The total costs of outpatient medical visits during treatment and
for stable disease off treatmentwere the product of the unit cost of
an outpatient visit by themean time spent in the stable disease on
and off therapy states, respectively.Wedid not include the costs of
imaging and laboratory tests because we assumed a similar utili-
zation of these resources in both groups.
We estimated the costs of progressive disease from a retro-
spective cost study that analyzed claims data from patients in-
cluded in the Surveillance, Epidemiology, and End Results (SEER)-
Medicare database from 1999 to 2003 [21]. This study reported the
average costs of Medicare parts A and B services provided in the
last 12 months of life for patients with various cancers, including
advanced stage NSCLC. We calculated the average monthly costs
of cancer care in the last 12 months of life from this study, and
multiplied these costs by the mean time spent in the progressive
disease state to obtain the mean costs of progressive disease.
We reported all costs in 2010 US dollars. When appropriate, we
adjusted the costs for inflation using the Consumer Price Index for
medical services as a reference guide. We did not include costs of
second-line chemotherapy in the analysis, and the patients in the
ECOG4599 trial had similar rates of second-line chemotherapy in
both groups. Table 2A shows the unit costs for all cost inputs in
both groups.
Data analysis
We discounted future years of life-expectancy, QALYs, and costs
at 3% per year. We calculated the incremental cost-effectiveness
ratio (ICER) and incremental cost-utility ratio (ICUR) of bevaci-
zumab and chemotherapy relative to chemotherapy alone by di-
viding the difference in total discounted costs between CBP and CP
by the difference in discounted life expectancy (ICER) and dis-
Table 2B – Transition probabilities.
CPbev CP
TP SDtx to SDtx 0.8948 0.8515
TP SDtx to FN 0.0028 0.0011
TP SDtx to Bleed 0.0024 0.0004
TP SDtx to PD 0.10 0.147
TP FN to Death 0.23 0.111
TP FN to SDtx 0.77 0.889
TP Bleed to Death 0.219 0.25
TP Bleed to SDoff 0.781 0.75
TP SDoff to SDoff 0.9 0.853
TP SDoff to PD 0.1 0.147
TP PD to PD 0.8926 0.8874
TP PD to death 0.1074 0.1126
Bleed, severe bleeding; FN, febrile neutropenia; PD, progressive dis-
ease; SDoff, stable disease off therapy; SDtx, stable disease on ther-
apy; TP, transition probability.counted QALYs (ICUR) between CPB and CP, respectively. We useda cost-effectiveness threshold of $100,000/QALY to determine if
the addition of bevacizumab to chemotherapy compared with
chemotherapy alone is cost-effective, taking the US government
health payer perspective.
Sensitivity analysis
We assessed the parameter uncertainty of the model by one-
way and probabilistic sensitivity analyzes (PSA). One-way sen-
sitivity analysis consisted of artificial variations in one model’s
parameter at a time, while holding the other parameters con-
stant. We then assessed the impact of varying single parameters
on incremental costs, QALYs, and ICUR.We used the 95% CI of the
hazard ratios for death and tumor progression reported in the trial
to vary the survival in each health state. We varied utilities in
stable disease states from the worst case scenario (cough, dys-
pnea, and pain) to the best case scenario (treatment responsewith
no symptoms) [15,16]. We varied the utility of PD and FN states
from theworst health state utility in our study (severe bleeding) to
the utility of stable disease on treatment state [15,17]. We varied
the utility of severe bleeding by 10%. We varied the number of
bevacizumab cycles from a minimum of 4 to a maximum of 15
cycles, to reflect a range of cycles going from the minimally rec-
ommended number of platinum-doublet cycles with no mainte-
nance [4] to continuation of bevacizumab for 3months after tumor
rogression [5,15]. We varied all other unit costs by 20% of the
ase case. Discount rates varied from 0% to 6% (Table 2A). We
epeated the one-way sensitivity analysis assuming a dose of 7.5
g/kg of bevacizumab while varying the other individual param-
ters within the same ranges used for the dose of 15 mg/kg. This
llowed us to estimate the cost-effectiveness and model robust-
ess of bevacizumab at the dose used in the AVAiL trial [22].
PSA consists of an analysis of the impact of simultaneous vari-
tions in allmodel’s parameters on the outcome variables, provid-
ng a comprehensive assessment ofmodel parameter uncertainty.
ur study focused the PSA on total costs, QALYs, and ICUR as
utcome variables. We varied the parameters by randomly draw-
ng values from reasonably assumed distributions for each param-
ter simultaneously. We assumed beta and Dirichlet distributions
or transition probabilities, beta distributions for utilities, and
amma distributions for costs with a standard error of 20%. We
hen ran a Monte Carlo simulation with 1000 iterations to obtain
andomvalues for incremental costs andQALYswith their respec-
ive ICURs. These values are illustrated in a cost-effectiveness
lane of incremental costs in the y axis and incremental QALYs in
he x axis. We then calculated the probability of bevacizumab be-
ng cost-effective under several ICUR thresholds (willingness-to-
ay) and illustrated these results in a cost-effectiveness accept-
bility curve. We performed all analysis in Microsoft Excel.
Results
Figure 2 shows the survival plots estimated from the model for
both groups superimposed with the Kaplan-Meier survival curves
reported in the ECOG 4599 trial. The model estimated undis-
counted mean overall survivals of 15.4 and 12.4 months for CPB
and CP groups, respectively. This compares to a mean overall sur-
vival of 15.9 and 12.1 months for the CPB and CP groups, respec-
tively, as estimated by the trial survival AUC.
Base case
Table 3 summarizes the base case results. Discounted life expec-
tancy was 1.24 years in CPB group, compared with 1.01 years in CP
group, for an absolute difference of 0.23 years. The difference in
life expectancywas entirely due to an increase in the time spent in
the stable disease on therapy state favoring the CPB group (0.71 vs.
0.29 years). The CP group spent more time in the stable disease off
841V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5therapy state than the CPB group (0.18 vs. 0.01 years), reflecting the
maintenance bevacizumab in the CBP group after the initial six
cycles, until disease progression or severe bleeding, as opposed to
no therapy in the CP group after six cycles (Table 2A). This partially
offset the survival advantage of bevacizumab seen in the stable
disease on therapy state, resulting in a mean PFS benefit of 0.25
years favoring bevacizumab. The PFS benefit accounted for the
mean overall survival benefit of the addition of bevacizumab,
since mean survival after disease progression was similar for the
two groups (0.52 and 0.54 years for the CPB and CP groups, respec-
tively). TreatmentwithCPB resulted in 0.66QALYs, comparedwith
0.53 QALYs in the CP group, for an absolute difference of 0.13
QALYs per patient. Mean total costs per patient were approxi-
mately $116,000 in the CPB group, comparedwith $44,000 in the CP
group, resulting in an incremental cost of adding bevacizumab of
approximately $72,000 per patient. The main contributor to the
difference in total costs was the drug utilization costs. The differ-
ence in costs of PD is due to a slightly shorter mean time spent in
PD state in the CPB group compared with the CP group. Relative to
CP, CPB resulted in $309,000 per life-year gained, and $560,000 per
QALY gained, respectively. FN and severe bleeding, the two toxic-
ities that resulted in treatment-related deaths in the ECOG4599
trial, accounted only minimally for differences in costs and sur-
vival (Tables 2A and 3).
Sensitivity analysis
Figure 3 shows the one-way sensitivity analysis represented by
tornado diagrams for incremental QALYs, total costs, and the
ICUR, respectively. Incremental QALYs were most sensitive, in a
decreasing order, to the survival in the stable disease on treatment
state (maximum range  0.07–0.20 incremental QALYs favoring
bevacizumab), the utility of the stable disease on treatment state,
and the survival in the progressive disease state. Incremental
costs were most sensitive, in a decreasing order, to the number of
bevacizumab cycles (maximumrangeUS$25,000–$95,000 for the
bevacizumab group), the acquisition costs of bevacizumab
(range  $58,000–$86,000), and the discount rate. The ICUR was
most sensitive to the survival in the stable disease on treatment
state for the bevacizumab group (max range  $363,000–
Table 3 – Base case results discounted at 3% per year.
Outcomes CPB CP Difference
Effectiveness
Life expectancy (years) 1.24 1.01 0.23
Progression-free
survival (years)
0.72 0.47 0.25
QALYs 0.66 0.53 0.13
Lifetime costs per patient
(US$)*
Drug utilization 70,284.75 646.96 69,637.79
Drug administration 4,239.87 1,495.24 2,744.63
Fever and neutropenia 25.32 4.37 20.95
Severe bleeding 19.65 1.33 18.32
Other adverse events 39.06 32.09 6.97
Outpatient visits 1,017.90 609.41 408.49
Progressive disease 40,283.71 41,500.96 1,217.25
Total 115,910.26 44,290.36 71,619.90
ICER (US$/life-years
gained)
308,981.58
ICUR (US$/QALY gained) 559,609.48
CP, carboplatin and paclitaxel; CPB, carboplatin, paclitaxel, and be-
vacizumab; ICER, incremental cost-effectiveness ratio; ICUR, incre-
mental cost-utility ratio; QALYs, quality-adjusted life years.
* Costs in 2010 US dollars.$1,012,000/QALY), the number of bevacizumab cycles (range $194,000–$743,000/QALY), and utility of the stable disease on
treatment state (range $393,000–$910,000/QALY). We calculated
a weighted average of the health utility states in the CPB group
using themean time spent in each health state as theweights. The
weighted average health utility in the CPB group was 0.534. This
allowed us to calculate the mean overall survival benefit that be-
vacizumab would have to generate in order to result in an ICUR of
$100,000/QALY. The addition of bevacizumab to chemotherapy
would have to increase the mean overall survival by 1.3 years in
order to result in an ICUR of US$100,000/QALY,while holding other
parameters constant. The acquisition cost of bevacizumab would
have to be approximately $885 for the addition of bevacizumab to
result in an ICUR of US$100,000/QALY, other parameters held
constant.
We repeated the one-way sensitivity analysis with bevaci-
zumab at 7.5 mg/kg instead of 15/mg/kg, reflecting a dose used in
the AVAiL trial [22]. We assumed that this 50% dose reduction
would reduce the acquisition cost of bevacizumab by 50%, while
all the other parameters of the model remained unchanged (in-
cluding survival in all health states, other costs, and utilities). In
this scenario, at base case, the addition of bevacizumab to chemo-
therapy resulted in an ICER of $159,000/Life-year gained and an
ICUR of $288,000/QALY. The one-way sensitivity analysis in this
scenario showed that the model is most sensitive to the same
parameters observed at the dose of 15mg/kg: survival in the stable
disease on therapy (CPB group), the number of cycles of bevaci-
zumab, and the utility of stable disease on therapy state (Fig. 4).
Probabilistic sensitivity analysis
Figure 5 shows the cost-effectiveness plane for bevacizumab and
chemotherapy compared with chemotherapy alone. Ninety per-
cent of the 1000 simulation iterations were located in the north-
east quadrant (bevacizumabplus chemotherapy results in gains in
QALYs at additional costs compared with chemotherapy alone),
whereas 10% of the iterationswere located in the northwest quad-
rant (bevacizumab plus chemotherapy results in loss of QALYs at
additional costs compared with chemotherapy alone, or bevaci-
zumab is dominated). The range of simulated values was0.18 to
0.39 incremental QALYs and $11,684 to $169,236 incremental costs
for bevacizumab and chemotherapy compared with chemother-
apy alone. The probabilities that bevacizumab is cost-effective
when added to chemotherapy were 0.2%, 1.2%, and 4.1%, for will-
ingness-to-pay thresholds of US$ 100,000/QALY, 150,000/QALY,
and 200,000/QALY, respectively (Fig. 6). At a threshold of $600,000/
QALY, bevacizumab had a probability of 50% of being cost-effec-
tive (Fig. 6).
Discussion
We performed a cost-utility analysis of the addition of bevaci-
zumab to chemotherapy compared with chemotherapy alone in
first-line chemotherapy for advanced NSCLC in patients with
nonsquamous tumor histologies, based on clinical outcomes from
the pivotal ECOG4599 trial [3]. At base-case, compared with che-
motherapy alone, the addition of bevacizumab prolonged life ex-
pectancy by approximately 3 months, improved QALYs by 0.13,
and had life-time incremental costs of approximately US$72,000
per patient treated with bevacizumab and chemotherapy. The re-
sultant ICUR of approximately $560,000/QALY indicates that this
intervention is not cost-effective based on commonly cited
thresholds in the US of $50,000 to $150,000/QALY, from the US
health payer perspective [23,24]. The best-case scenarios for the
most sensitive variables in the one-way sensitivity analysis (sur-
vival in the stable disease on treatment state and the number of
cycles of bevacizumab) resulted in ICURs of $363,000/QALY and
$194,000/QALY, respectively. The PSA revealed that the probabili-
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842 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5ties of bevacizumab being cost-effective when added to chemo-
therapy range from 0.2% to 1.2% for willingness-to-pay thresholds
of $100 to $150,000/QALY. Thus, the uncertainty analysis suggests
a very small likelihood that this intervention offers good value for
money.
A survey of oncologists suggested an implicit ICUR of $300,000/
QALY for them to recommend a specific cancer drug to patientswith
metastatic lung cancer. Our results suggest therefore that bevaci-
zumab is not cost-effective either from the payer or the clinician
perspective, despite its common use for this indication [25].
Three other studies have estimated the cost-effectiveness of
dding bevacizumab to chemotherapy in advanced nonsquamous
SCLC, taking the payer perspective [10–12]. Only one of these
ost-effectiveness analysis (CEAs) included QALYs as an outcome
f interest, but all three CEAs and our study used survival as a
ommon outcome measure to determine ICERs. Klein et al re-ported an ICER of $337,179 per life-year gained (LY) for carboplatin,
paclitaxel, and bevacizumab (as used in the ECOG 4599 trial) com-
paredwith cisplatin and pemetrexed, suggesting that the addition
of bevacizumab is not cost-effective when compared with more
recent and expensive regimens [10]. Grusenmeyer et al. [12] per-
ormed a CEA similar to our study, based on the ECOG 4599 trial,
nd reported an ICER of $345,762/LY, which is similar to the ICER
e report ($309,000/LY). Giuliani et al. [11] estimated the cost-ef-
ectiveness of cisplatin, gemcitabine, and bevacizumab compared
ith cisplatin and pemetrexed, taking the Italian payer perspec-
ive [22,26]. This study reported an ICER of €34,919/LY, and con-
luded that the combination of cisplatin, gemcitabine, and bevaci-
umab is cost-effective compared with cisplatin and pemetrexed.
everal aspects of this CEA limit the ability to extrapolate its re-
ults to the US health care system. First, bevacizumab and pem-
trexed are priced differently in the US and Italy, respectively.
evacizumab is more expensive than pemetrexed in the US (2009
SP of $5.75/mg and $4.94/mg for bevacizumab and pemetrexed,
espectively), while pemetrexed is more expensive than bevaci-
umab in Italy (€2.68/mg and €2.75/mg for bevacizumab and pem-
trexed, respectively) [11,18]. Second, the differences in currency
US$ vs. €) also limit the interpretation of the ICER reported by
iuliani et al. from the perspective of the US health payer. Third,
iuliani et al. [22] used the bevacizumab-based regimen described
n the AVAiL trial for their model. This regimen includes cisplatin,
emcitabine, and bevacizumab at a dose of 7.5 mg/Kg every 3
eeks, which is half of the dose used in the ECOG 4599 trial. Since
he ICER is most sensitive to the acquisition cost of bevacizumab,
he cost-effectiveness of the addition of bevacizumab will vary
ubstantially depending on the dose of bevacizumab considered in
CEA (7.5 vs. 15 mg/kg).
Our results and the previously reported CEAs suggest that the
ddition of bevacizumab at 15mg/kg is not cost-effective from the
ayer perspective compared with most commonly used chemo-
Fig. 3 – One-way sensitivity analysis of bevacizumab and
chemotherapy versus chemotherapy alone. Costs are given
in 2010 US dollars (US$). Administration cost bev alone,
costs of drug administration for bevacizumab alone during
maintenance bevacizumab treatment; administration cost
chemo alone, costs of drug administration of
chemotherapy (chemotherapy alone group); administration
cost chemo+bev, costs of drug administration of
chemotherapy plus bevacizumab (bevacizumab group);
bevacizumab cost, unit acquisition cost of bevacizumab; #
cycles bevacizumab, number of cycles of bevacizumab; #
cycles carbo (bev group), number of cycles of carboplatin
(bevacizumab group); # cycles carbo (chemo group),
number of cycles of carboplatin (chemotherapy alone
group); ICUR, incremental cost-utility ratio; PD cost per
month, monthly costs of managing progressive disease;
QALY, quality-adjusted life year; time in PD, survival in the
progressive disease state (chemotherapy alone group);
time in PD bev, survival in the progressive disease state
(bevacizumab group); time in SDoff, survival in the stable
disease off treatment state (chemotherapy alone group);
time in SDoff bev, survival in the stable disease off
treatment state (bevacizumab group); time in SDtx,
survival in the stable disease on treatment state
(chemotherapy alone group); time in SDtx bev, survival in
the stable disease on treatment state (bevacizumab group);
utility FN, health state utility of fever and neutropenia
state; utility PD, health state utility of progressive disease
state; utility SDoff, health state utility of stable disease off
treatment state; utility SDtx: health state utility of stable
disease on treatment state.
843V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5therapy regimens. The use of bevacizumab at 7.5 mg/kg, however,
may be more cost-effective compared with chemotherapy alone
than bevacizumab at 15 mg/kg. If we assume that the addition of
bevacizumab at 7.5mg/kg results in the same overall survival ben-
efit observed in the ECOG 4599 trial compared with chemotherapy
alone, bevacizumab would result in an ICER of $159,000/LY and an
ICUR of $288,000/QALY, which is more cost-effective than bevaci-
zumab at 15 mg/kg as we observed in our study. Future CEAs
should evaluate the cost-effectiveness of the addition of bevaci-
zumab at 7.5 mg/kg to cisplatin and gemcitabine (as in the AVAiL
trial) relative to cisplatin and pemetrexed from the US health
payer perspective in order to determine if lower doses of bevaci-
zumab offer good value for money. Cisplatin and pemetrexed
would be an appropriate comparator for this CEA, because a recent
trial suggested that cisplatin and pemetrexed are superior to cis-
platin and gemcitabine in non-squamous NSCLC [26].
One potential cost-effective strategy is to develop predictive
molecular biomarkers to guide the use of new cancer drugs. Pre-
Fig. 4 – One-way sensitivity analysis of bevacizumab at 7.5 mg/
kg in addition to chemotherapy compared with chemotherapy
alone. This one-way sensitivity analysis assumed that the
lower dose of bevacizumab reduced the acquisition cost of
bevacizumab by 50%. We assumed that all other parameters of
the model remained unchanged and were the same parameters
we used for the base case and one-way sensitivity analysis of
bevacizumab at 15 mg/kg as shown in Table 3 and Figure 3,
respectively. Costs are given in 2010 US dollars (US$).
Administration cost chemo+bev, costs of drug administration of
chemotherapy plus bevacizumab (bevacizumab group);
bevacizumab cost, unit acquisition cost of bevacizumab at 7.5
mg/kg; # cycles bevacizumab, number of cycles of bevacizumab;
# cycles carbo (bev group), number of cycles of carboplatin
(bevacizumab group); # cycles carbo (chemo group), number of
cycles of carboplatin (chemotherapy alone group); discount rate,
discount rate; ICUR, incremental cost-utility ratio; PD cost per
month, monthly costs of managing progressive disease; QALY,
quality-adjusted life year; time in PD bev, survival in the
progressive disease state (bevacizumab group); time in PD
chemo, survival in the progressive disease state (chemotherapy
alone group); time in SDoff chemo, survival in the stable disease
off treatment state (chemotherapy alone group); time in SDtx,
survival in the stable disease on treatment state (chemotherapy
alone group); time in SDtx bev, survival in the stable disease on
treatment state (bevacizumab group); utility PD, health state
utility of progressive disease state; utility SDoff, health state
utility of stable disease off treatment state; utility SDtx: health
state utility of stable disease on treatment state.dictive biomarkers allow for the selection of patients who aremore likely to benefit from a particular treatment, while sparing
patientswhowill not benefit from incurring unnecessary financial
costs and toxicities. The EGFR gene copy number is an example of
a molecular predictive biomarker used to select lung cancer pa-
tients who are more likely to benefit from EGFR inhibitors such as
erlotinib [27]. One CEA suggested that selecting advanced NSCLC
patients for second-line treatment with erlotinib based on high
EGFR gene copy numbers wasmore cost-effective than treating all
patients with this drug, when both strategies were compared with
Best Supportive Care [28]. Unfortunately, there are no validated
biomarkers that predict which patients are more likely to benefit
from the addition of bevacizumab to chemotherapy in first-line
treatment for advanced NSCLC. Our results suggested that bevaci-
zumabwould be cost-effective if it improvedmeanoverall survival
in advanced NSCLC by 1.3 years. The ECOG4599 trial showed a
2-year overall survival of 23% in the bevacizumab arm, compared
with 15% in the chemotherapy alone arm [3]. The 8% difference in
2-year OS suggests that some patients may have a survival benefit
from bevacizumab in the magnitude that could make this drug
cost-effective for this subgroup. None of the subgroup analysis in
the ECOG4599 trial suggested a patient characteristic that pre-
dicted a survival benefit of more than one year. Therefore, the use
of bevacizumab could bemade cost-effective if guided by amolec-
ular biomarker that identifies the small subgroup of patients who
derive a greater benefit from this drug. Most phase III clinical trials
of molecularly-targeted drugs, including bevacizumab, have
shown at best modest improvements in survival outcomes when
these drugs were given to unselected patient populations [29–31].
Giving the high costs of these target drugs, their use is unlikely to
be cost-effective unless guided by predictive biomarkers.
Bevacizumab’s high acquisition cost was themain driver of the
cost-effectiveness of this drug in our study. Lower acquisition
costs of bevacizumab would therefore make this drug substan-
tially more cost-effective, improving its value for money. We esti-
Fig. 5 – Cost-effectiveness plane of bevacizumab plus
chemotherapy versus chemotherapy alone. Incremental
costs (2010 US dollars [US$]) and quality-adjusted life years
(QALYs) were obtained from a Monte Carlo simulation with
1000 iterations. Incremental costs represent the difference
in lifetime direct medical costs of adding bevacizumab to
chemotherapy compared with chemotherapy alone.
Incremental QALYs represent the difference in QALYs of
bevacizumab plus chemotherapy compared with
chemotherapy alone. Ninety percent of the simulations
were within the Northeast quadrant, where the addition of
bevacizumab to chemotherapy resulted in gain in QALYs
and costs, whereas 10% of the simulations were in the
Northwest quadrant, where the addition of bevacizumab to
chemotherapy resulted in loss of QALYs and increase in
costs.
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844 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5mated bevacizumab’s acquisition cost from its Medicare Average
Sales Price (ASP) in 2010, which prices the drug at $58.44 per 10mg
used. This price followed the first approval for bevacizumab use in
metastatic colorectal cancer, at a dose of 5 mg/kg every 2 weeks
[32]. The bevacizumab dose used in the lung cancer ECOG4599 trial
was 15 mg/kg every 3 weeks, which represents the double of the
colorectal cancer dose. Bevacizumab could be more cost-effective
in lung cancer if the drugwas differentially priced on amg/kg basis
for this condition.
The case of bevacizumab in advanced NSCLC represents an
example of how new costly oncology products for common can-
cers can impact the health care system. Medicare part B drug ex-
penditures, which includesmost of the cancer drugs, rose from $3
billion in 1997 to $11 billion in 2004, a 267% increase compared
with a 47% increase in overall Medicare spending in the same
period, andmost of this increase in expenditures is due to rising in
cancer drug prices [8]. The rising costs of new cancer drugs has
utpaced the incremental benefit to patient outcomes these drugs
rovide, which have remained modest in most cases. If we con-
ervatively assume that 50% of all newly diagnosed patients with
dvanced NSCLC receive bevacizumab, the annual US health care
ystem expenditures would increase by an estimated $3.1 billion,
ut the overall survival of patients treated with this drug would
mprove on average by 2 to 3 months. This trend in cancer drug
xpenditures is clearly unsustainable, and patients may be al-
eady experiencing harmful consequences from increasing drug
osts, despite the small benefit these drugs confer to patients. A
urvey of cancer patients has shown that up to 20% of them have
xperienced more than $10,000 in out-of-pocket expenses during
heir treatment, and at least 20% of cancer patients have reported
a large amount of distress” directly related to their financial treat-
ent costs [33]. Whether we accept or not CEAs as a guide for
esource allocation in cancer care, our society will be forced one
ay or the other to decide the amount of resources to spend in
xpensive cancer treatments that are only modestly effective.
Recent randomized trials have suggested a survival benefit for
he use of maintenance therapy with single agents such as pem-
trexed or erlotinib after 4 cycles of chemotherapy with platinum
oublets [34,35]. The survival benefit conferred by maintenance
herapy strategies comes at the expense of increased drug utiliza-
ion and costs. Therefore, our model could have resulted in a dif-
Fig. 6 – Cost-effectiveness acceptability curve of bevacizuma
Costs given in US dollars (US$). Probabilistic sensitivity anal
iterations. Results reflect the probabilities that bevacizumab
chemotherapy alone under several thresholds of willingnes
QALY, quality-adjusted life year.erent ICUR for the addition of bevacizumab to carboplatin andpaclitaxel had we included a maintenance strategy in the control
arm with either erlotinib or pemetrexed. The lack of a mainte-
nance therapy in our model, however, does not invalidate our re-
sults, because the use ofmaintenance therapy inNSCLC remains a
controversial topic. Some oncologists argue that the randomized
trials ofmaintenance therapywere flawed because in their control
arms only about 20% of patients received the drugs used in the
maintenance strategy of the intervention arm, which brings into
question whether the benefit seen in these trials were due to a
maintenance strategy per se or simply due to the difference in
utilization rates of active second-line therapies between the inter-
vention and control arms [36]. Further CEAsmay explore the cost-
effectiveness of bevacizumab-based regimens versus non-bevaci-
zumab regimens that include a maintenance strategy.
Several limitations apply to our study. Our study did not
evaluate the cost-utility of bevacizumab in clinically-defined
subgroups of patients. None of the subgroup analysis in the
ECOG4599, however, revealed a subpopulation that had a survival
benefit from bevacizumab in the magnitude that would make
this drug cost-effective for this subgroup [3]. Our model did not
account for the effect of response rates on QALYs, although
studies suggest a better health utility state for patients with
responding disease [15,16]. This could have offset some of the
beneficial effects of bevacizumab, since its addition to chemo-
therapy has improved response rates by 20%. We did not in-
clude the results of the published AVAiL trial, which compared
cisplatin, gemcitabine, and bevacizumab (at doses of 7.5 and 15
mg/kg) with cisplatin and gemcitabine alone [22,37], because
the initial report did not include overall survival data at the time
we conducted our study [22]. Our model did not account for the
costs of blood tests or imaging studies, although the utilization
of these studies was identical for both trial groups during the
clinical trial and were likely similar after tumor progression,
and therefore the addition of these parameters would very un-
likely have changed our conclusions. Our model did not account
for the effects of second or third-line therapies on costs and
outcomes, because the ECOG 4599 trial did not specify the sur-
vival outcomes for patients who received or did not receive fur-
ther therapy after tumor progression from first-line therapy,
and the trial did not report in details the types of second-line
treatments offered. The use of second-line chemotherapy, how-
d chemotherapy compared with chemotherapy alone.
was based on the Monte Carlo simulation with 1000
chemotherapy are cost-effective compared with
pay for 1 year of perfect health-related quality of life.b an
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845V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 3 6 – 8 4 5received second-line chemotherapy in the CPB and CP arms,
respectively) [3]. In addition, since survival in the progressive
disease state was similar between the two groups in the model,
the use of second-line therapies and their impact on costs and
outcomes are probably similar for both groups and including
them in the model would unlikely change our results substantially.
Ourmodelwas static andassumednodifferences indrugacquisition
costs over time and no differences in costs across different payers.
This may have overestimated the costs of bevacizumab, because its
costswill likely decreasewhen this drug goes off-patent andbiosimi-
larsbecomeavailable in themarket, andhealth insurancesmayhave
agreements with drug suppliers that allow for price discounts when
paying for bevacizumab. Lastly, our study took the perspective of the
US health care system, and not the societal perspective, which is the
recommended approach from CEA guidelines [23].
In conclusion, bevacizumab is not cost-effective when added
o first-line chemotherapy in unselected patients with ad-
anced NSCLC of non-squamous histology from the US health
ayer perspective. Bevacizumab’s cost of providing an addi-
ional year of perfect quality of life was approximately $560,000
n this setting. Other drugs, such as pemetrexed, or bevaci-
umab at 7.5 mg/kg, may be more cost-effective than bevaci-
umab at 15 mg/kg when used as first-line chemotherapy. Fu-
ure research should focus on developing predictive molecular
iomarkers to select patients in whom the use of bevacizumab
s cost-effective. Our study may help decision-makers to make
nformed decisions about resource allocation for NSCLC cancer
are.
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